<DOC>
	<DOCNO>NCT01938625</DOCNO>
	<brief_summary>The purpose study evaluate effect steady-state ( amount drug administer ( give time period equal amount drug eliminate period ) simeprevir daclatasvir steady-state pharmacokinetics ( medication body ) cyclosporine ( applicable Part 1 ) tacrolimus administer combinational regimen post-orthotopic liver transplantation ( OLT ) participant recurrent hepatitis C virus ( HCV ) genotype 1b infection effectiveness 24-week treatment regimen contain simeprevir , daclatasvir , ribavirin ( RBV ) respect proportion HCV genotype 1b infect post-OLT participant achieve sustain virologic response 12 week end treatment .</brief_summary>
	<brief_title>A Study Pharmacokinetics , Efficacy , Safety , Tolerability , Combination Simeprevir ( TMC435 ) , Daclatasvir ( BMS-790052 ) , Ribavirin ( RBV ) Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation</brief_title>
	<detailed_description>This open-label ( participant study know identity intervention ) multicenter ( study conduct multiple site ) study . This study conduct 2 part . Both part study consist screen phase ( 4 week ) , treatment period ( 24 week ) , post-treatment follow-up ( 24 week ) . A total 30 participant enrol Part 1 Part 2 study . A minimum 9 participant plan receive cyclosporine stable immunosuppressant therapy minimum 9 participant plan receive tacrolimus stable immunosuppressant therapy Part 1 . All participant receive tacrolimus stable immunosuppressant therapy Part 2 . In Part 1 study , participant Metavir score F1-F2 , receive combination study drug - simeprevir , daclatasvir , ribavirin 24 week . In Part 2 study , participant Metavir score F1-F4 receive dose regimen study drug base data Part 1 study . Safety evaluation include assessment adverse event , clinical laboratory test , urinalysis , electrocardiogram , vital sign , physical examination . The total study duration participant approximately 52 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Liver transplant 6 month 10 year prior screen visit Hepatitis C virus ( HCV ) genotype 1 subtype b infection confirm screen Screening HCV ribonucleic acid level great 10,000 IU/mL HCV treatmentna√Øve participant must receive post orthotopic liver transplant treatment approve investigational drug treatment HCV Receiving stable immunosuppressant therapy ( ie , change dose last month ) cyclosporine ( allow Part 1 ) tacrolimus 3 month prior screen visit Evidence acute chronic hepatic decompensation liver transplantation ( include ascites , bleed varix hepatic encephalopathy ) Any liver disease nonHCV etiology , include current evidence graft rejection except presence liver steatosis Any clinically significant disease opinion investigator would exacerbate known effect ribavirin Coinfection HCV another genotype genotype 1b , HIV type 1 2 ( positive HIV1 HIV2 antibodies test screen ) , hepatitis B virus ( hepatitis B surface antigen positive ) Multiorgan transplant include heart , lung , pancreas , kidney</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Recurrent Chronic Hepatitis C</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Simeprevir</keyword>
	<keyword>Daclatasvir</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Orthotopic Liver Transplantation</keyword>
	<keyword>TMC435</keyword>
	<keyword>BMS-790052</keyword>
	<keyword>RBV</keyword>
</DOC>